Versameb is focusing on the discovery and development of innovative, next-generation RNA-based drugs.
Versameb AG is a preclinical-stage biopharmaceutical company located in Basel, Switzerland managed by an experienced scientific and business pharmaceutical industry team.The company’s focus is the development of novel RNA-based therapeutics. Versameb’s proprietary VERSagile technology platform enables efficient development of functional mRNA molecules for customized protein expression and modification in multiple disease areas with high unmet medical need.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jul 15, 2020 | Seed | Fr6M | — | — | — | Detail |
| Oct 17, 2019 | Seed | Fr6.40M | — | — | — | Detail |
| Dec 27, 2018 | Seed | Fr5.30M | 1 | — | — | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Penny Schiffer
|
— | Seed |